EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access

One Step Ahead: Preventing Tumor Adaptation to Immune Therapy

Erica L Braverman, Giuliana P Mognol, Andy J Minn, Dario A A Vignali, Judith A Varner iD

American Society of Clinical Oncology Educational Book · 2025-06 · 45 (3)

DOI: 10.1200/edbk-25-481556 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift American Society of Clinical Oncology Educational Book, 2025-06. Verfasst von Erica L Braverman und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Immunology, University of Pittsburgh School of Medicine, Pittsburgh, PA. Hauptthemen laut MEDLINE: Neoplasms, Immunotherapy, Immune Checkpoint Inhibitors. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 117 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, NIAID NIH HHS, NIDCR NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Immune checkpoint inhibitors are cancer therapeutics that have shown remarkable success in extending lives in many cancers, including melanoma, MSI-high cancers, and other cancers. However, these therapeutics have not shown benefit for many patients with cancer, especially those with advanced cancer diagnoses. In addition, many patients develop resistance to these therapeutics and/or life-altering adverse events that can include cardiotoxicity, pneumonitis, thyroiditis, pancreatitis, and hepatitis. Extensive efforts to improve cancer care by uncovering mechanisms of resistance to immune therapy in solid tumors have led to identification of new sources of resistance and to the development of new approaches to activate or sustain antitumor immunity. Chronic stimulation of T cells by tumors and by checkpoint inhibitors can lead to a progressive state of T-cell exhaustion. Chronic T-cell activation by the tumor microenvironment (TME) or immune therapeutics can upregulate the expression and function of alternate checkpoints, including the T-cell protein LAG-3. Persistent interferon signaling in the TME can drive epigenetic changes in cancer cells that enable tumors to counter immune activation and disrupt tumor cell elimination. In addition, immune-suppressive macrophages can flood tumors in response to signals from dying tumor cells, further preventing effective immune responses. New clinical developments and/or approvals for therapies that target alternate immune checkpoints, such as the T-cell checkpoint LAG-3; myeloid cell proteins, such as the kinase phosphoinositide 3-kinase gamma isoform; and chronic interferon signaling, such as Jak 1 inhibitors, have been approved for cancer care or shown promise in recent clinical trials.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NeoplasmsImmunotherapyImmune Checkpoint InhibitorsHumansTumor Microenvironment

Substanzen

Immune Checkpoint Inhibitors

Autor:innen und Institutionen

  • Department of Immunology, University of Pittsburgh School of Medicine, Pittsburgh, PA.
  • Department of Pediatrics, Division of Pediatric Hematology/Oncology, University of Pittsburgh School of Medicine, Pittsburgh, PA.
  • Moores Cancer Center, University of California, San Diego, La Jolla, CA.
  • Institute for Immunology and Immune Health, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA.
  • Abramson Family Cancer Research Institute, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA.
  • Tumor Microenvironment Center, UPMC Hillman Cancer Center, Pittsburgh, PA.

ORCID-Profile: Judith A Varner

Förderung

  • NCI NIH HHS
  • NIAID NIH HHS
  • NIDCR NIH HHS

Zitieren

APA

Braverman, E. L., Mognol, G. P., Minn, A. J., Vignali, D. A. A., & Varner, J. A. (2025). One Step Ahead: Preventing Tumor Adaptation to Immune Therapy. American Society of Clinical Oncology Educational Book, 45(3). https://doi.org/10.1200/edbk-25-481556

Vancouver

Braverman EL, Mognol GP, Minn AJ, Vignali DAA, Varner JA. One Step Ahead: Preventing Tumor Adaptation to Immune Therapy. American Society of Clinical Oncology Educational Book. 2025;45(3). doi:10.1200/edbk-25-481556

BibTeX
@article{Braverman2025,
  author = {Braverman, Erica L and Mognol, Giuliana P and Minn, Andy J and Vignali, Dario A A and Varner, Judith A},
  title = {One Step Ahead: Preventing Tumor Adaptation to Immune Therapy},
  journal = {American Society of Clinical Oncology Educational Book},
  year = {2025},
  volume = {45},
  number = {3},
  doi = {10.1200/edbk-25-481556}
}
Kostenlos starten →